Semizarov D - Search Results

1

Endothelin signaling in osteoblasts: global genome view and implication of the calcineurin/NFAT pathway.

Van Sant C, Wang G, Anderson MG, Trask OJ, Lesniewski R, Semizarov D. Van Sant C, et al. Among authors: semizarov d. Mol Cancer Ther. 2007 Jan;6(1):253-61. doi: 10.1158/1535-7163.MCT-06-0574. Mol Cancer Ther. 2007. PMID: 17237284

2

Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains.

Olejniczak ET, Van Sant C, Anderson MG, Wang G, Tahir SK, Sauter G, Lesniewski R, Semizarov D. Olejniczak ET, et al. Among authors: semizarov d. Mol Cancer Res. 2007 Apr;5(4):331-9. doi: 10.1158/1541-7786.MCR-06-0367. Mol Cancer Res. 2007. PMID: 17426248 Free article.

3

A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax).

Lam LT, Lu X, Zhang H, Lesniewski R, Rosenberg S, Semizarov D. Lam LT, et al. Among authors: semizarov d. Mol Cancer Ther. 2010 Nov;9(11):2943-50. doi: 10.1158/1535-7163.MCT-10-0427. Epub 2010 Sep 9. Mol Cancer Ther. 2010. PMID: 20829195

4

Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways.

Liu X, Han EK, Anderson M, Shi Y, Semizarov D, Wang G, McGonigal T, Roberts L, Lasko L, Palma J, Zhu GD, Penning T, Rosenberg S, Giranda VL, Luo Y, Leverson J, Johnson EF, Shoemaker AR. Liu X, et al. Among authors: semizarov d. Mol Cancer Res. 2009 Oct;7(10):1686-92. doi: 10.1158/1541-7786.MCR-09-0299. Epub 2009 Oct 13. Mol Cancer Res. 2009. PMID: 19825992 Free article.

5

An algorithm for classifying tumors based on genomic aberrations and selecting representative tumor models.

Lu X, Zhang K, Van Sant C, Coon J, Semizarov D. Lu X, et al. Among authors: semizarov d. BMC Med Genomics. 2010 Jun 22;3:23. doi: 10.1186/1755-8794-3-23. BMC Med Genomics. 2010. PMID: 20569491 Free PMC article.

6

Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152.

Guo J, Anderson MG, Tapang P, Palma JP, Rodriguez LE, Niquette A, Li J, Bouska JJ, Wang G, Semizarov D, Albert DH, Donawho CK, Glaser KB, Shah OJ. Guo J, et al. Among authors: semizarov d. Pharmacogenomics J. 2009 Apr;9(2):90-102. doi: 10.1038/tpj.2008.20. Epub 2009 Feb 3. Pharmacogenomics J. 2009. PMID: 19188929

7

siRNA-mediated gene silencing: a global genome view.

Semizarov D, Kroeger P, Fesik S. Semizarov D, et al. Nucleic Acids Res. 2004 Jul 22;32(13):3836-45. doi: 10.1093/nar/gkh714. Print 2004. Nucleic Acids Res. 2004. PMID: 15272085 Free PMC article.

8

Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics.

Xiao Z, Xue J, Semizarov D, Sowin TJ, Rosenberg SH, Zhang H. Xiao Z, et al. Among authors: semizarov d. Int J Cancer. 2005 Jul 1;115(4):528-38. doi: 10.1002/ijc.20770. Int J Cancer. 2005. PMID: 15688426

9

Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo.

Li L, Lin X, Staver M, Shoemaker A, Semizarov D, Fesik SW, Shen Y. Li L, et al. Among authors: semizarov d. Cancer Res. 2005 Aug 15;65(16):7249-58. doi: 10.1158/0008-5472.CAN-04-4426. Cancer Res. 2005. PMID: 16103076

10

Specificity of short interfering RNA determined through gene expression signatures.

Semizarov D, Frost L, Sarthy A, Kroeger P, Halbert DN, Fesik SW. Semizarov D, et al. Proc Natl Acad Sci U S A. 2003 May 27;100(11):6347-52. doi: 10.1073/pnas.1131959100. Epub 2003 May 13. Proc Natl Acad Sci U S A. 2003. PMID: 12746500 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32 results

Search Page

Filters